BiotechTube
Molsid

Molsid

Paris, France· Est.
molsid.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Molsid is a private, innovative biotech/medtech company addressing the critical global challenge of antimicrobial resistance (AMR) through rapid diagnostics. Its core technology is the SmartID® platform of fluorogenic biotracers, which enable the detection of specific bacterial enzyme activity, such as beta-lactamases, directly from primary clinical samples in as little as two hours. The company has two main product lines: 'Early Warning Beta-lactamases Detection' tests and 'Rapid Antimicrobial Susceptibility Testing' (AST) kits, positioning it in the growing market for rapid, actionable infectious disease diagnostics.

Infectious Diseases

Technology Platform

SmartID® platform of fluorogenic molecular probes (biotracers) that emit a fluorescent signal upon cleavage by specific bacterial enzymes, enabling rapid, culture-free detection of enzyme activity for diagnostics.

Opportunities

The global push for antibiotic stewardship and the rising prevalence of AMR create a large, growing market for rapid diagnostics.
Molsid's technology, capable of providing results in ~2 hours from primary samples, addresses a critical speed gap in current clinical workflows.
Expansion beyond beta-lactamases to other resistance mechanisms and infection types represents a significant pipeline opportunity.

Risk Factors

Key risks include challenges in commercial adoption and displacing entrenched laboratory methods, navigating complex regulatory pathways for IVDs in key markets like the US, and intense competition from both large diagnostics corporations and other startups.
The enzyme-specific detection approach may not cover all resistance mechanisms.

Competitive Landscape

Molsid competes in the rapid microbiology diagnostics space against large players like bioMérieux (VITEK, ETEST), Becton Dickinson (Phoenix), and Roche, as well as molecular diagnostic companies and startups developing rapid phenotypic/molecular tests. Differentiation is based on the unique fluorogenic probe technology offering speed (direct from sample), specificity for enzyme activity, and potential cost advantages compared to complex molecular platforms.

More companies in Diagnostics & Precision Medicine →More companies in France →